Recruiting
A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Pediatric Participants With Moderate to Severe Plaque Psoriasis - IM011-126
Updated: 31 October, 2024 | ClinicalTrials.gov
Phase
Gender(s)
Age Range
Location(s)
Recruiting
Inclusion Criteria: - Males and females aged 12 to <18 years for Cohort 1. Males and females aged 4 to <12 years for Cohort 2. - Plaque psoriasis for at least 6 months - Moderate to severe disease - Candidate for phototherapy or systemic therapy - Must have completed the Week 52 treatment period in Part A or B for long-term extension (LTE) period Exclusion Criteria: - Participants weighing ≤ 30.0 kg at screening for Cohort 1 (age 12 to < 18 years), Part A and Part B. Participants weighing ≤ 18.0 kg at screening for Cohort 2 (age 4 to < 12 years), Part A and Part B. - Other forms of psoriasis - History of recent infection - Prior exposure to deucravacitinib (BMS-986165) or active comparator - Evidence of active TB for LTE period Other protocol-defined inclusion/exclusion criteria apply
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
